Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Repeated scanning ultrasound in the absence of a therapeutic agent removes amyloid-β and restores memory in an Alzheimer’s disease mouse model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our results support previous studies showing improved behaviour in AD mouse models associated with enhanced microglial amyloid plaque phagocytosis in response to scanning ultrasound69, and treatment with IL-33 that signals exclusively via MyD8870.”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [69]
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“An entire series of sections was processed for Campbell-Switzer silver staining (36) using a protocol available online at http://neuroscienceassociates.”
MethodScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Ab is elevated in the AD brain because of the increased production of this peptide and its impaired removal (4, 5).”
BackgroundDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 1×
“At the age of 12 to 13 months, APP23 mice have a substantial plaque burden and spatial memory deficits (17).”
BackgroundSelf-citationTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Self-citationAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 1×
“Recent therapeutic strategies have targeted both processes (6), including the inhibition of secretase enzymes to reduce Ab production, as well as active and, in particular, passive immunization approaches for boosting Ab clearance.”
The secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799 · cited 1×
“Inhibition of secretases affects additional substrates with potential off-target effects (7), and passive immunization may be costly once effectiveness is demonstrated in clinical trials (8).”
BackgroundNecula, M., Kayed, R., Milton, S., & Glabe, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608207200 · Cited by 680
Immune activation in brain aging and neurodegeneration: too much or too little?
Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679 · cited 1×
“To avoid potentially excessive immune activation in a clinical setting (30), the ultrasound treatment regimen could possibly be done stepwise, covering one brain area at a time.”
BackgroundKinoshita, M., McDannold, N., Jolesz, F. A., & Hynynen, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604318103 · Cited by 645 · cited 2×
“Whereas we only coupled ultrasound with microbubbles, previous studies in rodents evaluated ultrasound for the delivery of therapeutic agents, such as antibodies (31, 32), viral vectors (33), and dextran of different sizes (9, 10).”
MethodMR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study
Lipsman, N., Schwartz, M. L., Huang, Y., Lee, L., Sankar, T., Chapman, M., Hynynen, K., & Lozano, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70048-6 · Cited by 604 · cited 1×
“Recently, a proof-of-concept study of using magnetic resonance–guided focused ultrasound to treat tremor and chronic pain has been successfully completed (15).”
BackgroundMcDannold, N., Arvanitis, C. D., Vykhodtseva, N., & Livingstone, M. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0128 · Cited by 588
Hutchinson, E. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2985 · Cited by 532
Morrison, H. W., & Filosa, J. A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-4 · Cited by 506 · cited 1×
“Skeleton analysis A skeleton analysis to obtain the most accurate tree geometry possible was applied to quantifymicroglialmorphology in images obtained from fixed brains as described (37).”
MethodAnti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382
Jordão, J. F., Ayala-Grosso, C. A., Markham, K., Huang, Y., Chopra, R., McLaurin, J., Hynynen, K., & Aubert, I. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010549 · Cited by 378 · cited 1×
“Whereas we only coupled ultrasound with microbubbles, previous studies in rodents evaluated ultrasound for the delivery of therapeutic agents, such as antibodies (31, 32), viral vectors (33), and dextran of different sizes (9, 10).”
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351
Jordão, J. F., Thévenot, E., Markham-Coultes, K., Scarcelli, T., Weng, Y.-Q., Xhima, K., O'Reilly, M., Huang, Y., McLaurin, J., Hynynen, K., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.05.008 · Cited by 326 · cited 2×
“Because the effect on Ab plaques was very modest, the authors of this study suggested that focused ultrasound would best be suited as a delivery tool, for example, to boost the uptake of peripherally administered anti-Ab antibodies (34).”
BackgroundActive and passive immunotherapy for neurodegenerative disorders
Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250 · cited 1×
“org 1 tions, different mechanisms have been proposed to remove Ab from the brain (22, 23), with variable effects on microglial activation (20, 24).”
BackgroundDirect observations of ultrasound microbubble contrast agent interaction with the microvessel wall
Caskey, C. F., Stieger, S. M., Qin, S., Dayton, P. A., & Ferrara, K. W. (2007) · The Journal of the Acoustical Society of America · doi:10.1121/1.2747204 · Cited by 226 · cited 1×
“This activity has been associated with a range of effects, including the displacement of the vessel wall through dilation and contraction (11, 12).”
BackgroundThévenot, E., Jordão, J. F., O'Reilly, M. A., Markham, K., Weng, Y.-Q., Foust, K. D., Kaspar, B. K., Hynynen, K., & Aubert, I. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.013 · Cited by 202 · cited 1×
“Whereas we only coupled ultrasound with microbubbles, previous studies in rodents evaluated ultrasound for the delivery of therapeutic agents, such as antibodies (31, 32), viral vectors (33), and dextran of different sizes (9, 10).”
Multiphoton Imaging of Ultrasound/Optison Mediated Cerebrovascular Effects in vivo
Raymond, S. B., Skoch, J., Hynynen, K., & Bacskai, B. J. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600336 · Cited by 174
Optimization of the Ultrasound-Induced Blood-Brain Barrier Opening
Konofagou, E. E. (2012) · Theranostics · doi:10.7150/thno.5576 · Cited by 173
Noninvasive and localized neuronal delivery using short ultrasonic pulses and microbubbles
Choi, J. J., Selert, K., Vlachos, F., Wong, A., & Konofagou, E. E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105116108 · Cited by 159
Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118
Wu, S.-Y., Tung, Y., Marquet, F., Downs, M. E., Sánchez, C. S., Chen, C. C., Ferrera, V. P., & Konofagou, E. E. (2014) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2014.2992 · Cited by 102 · cited 1×
“This could be facilitated by the recent development of advanced methods, such as passive cavitation detection, which is currently being evaluated in both rodents and primates (29).”
MethodChoi, J. J., Wang, S., Brown, T. R., Small, S. A., Duff, K., & Konofagou, E. E. (2008) · Ultrasonic Imaging · doi:10.1177/016173460803000304 · Cited by 99
Frost, J. L., Liu, B., Kleinschmidt, M., Schilling, S., Demuth, H., & Lemere, C. A. (2012) · Neurodegenerative Diseases · doi:10.1159/000335913 · Cited by 82
Henderson, S. J., Andersson, C., Narwal, R., Janson, J., Goldschmidt, T. J., Appelkvist, P., Bogstedt, A., Steffen, A.-C., Haupts, U. M., Tebbe, J., et al. (2013) · Brain · doi:10.1093/brain/awt308 · Cited by 78
Fowler, S. W., Chiang, A. C. A., Savjani, R. R., Larson, M. E., Sherman, M. A., Schuler, D. R., Cirrito, J. R., Lesne, S. E., & Jankowsky, J. L. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0572-14.2014 · Cited by 77
Rasool, S., Martínez‐Coria, H., Wu, J., LaFerla, F. M., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 76 · cited 1×
“org 1 tions, different mechanisms have been proposed to remove Ab from the brain (22, 23), with variable effects on microglial activation (20, 24).”
BackgroundAlonso, A., Reinz, E., Fatar, M., Hennerici, M. G., & Meairs, S. P. (2011) · Brain Research · doi:10.1016/j.brainres.2011.07.006 · Cited by 69 · cited 1×
“After BBBdisruption by ultrasound, albumin enters the brainwhere it is rapidly phagocytosed by glial cells but not by neurons (27).”
BackgroundSeip, R., Chin, C. T., Hall, C. S., Raju, B. I., Ghanem, A., & Tiemann, K. (2009) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2009.2028874 · Cited by 61
Therapeutic Albumin Binding to Remove Amyloid-β
Costa, M., Ortiz, A. M., & Jorquera, J. I. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111139 · Cited by 53
In Vitro Amyloid-β Binding and Inhibition of Amyloid-β Self-Association by Therapeutic Albumin
Milojevic, J., Costa, M., Ortiz, A. M., Jorquera, J. I., & Melacini, G. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131169 · Cited by 47
Clinical Trials and Drug Development
Mahipal, A. (2014) · Cancer Control · doi:10.1177/107327481402100301 · Cited by 8
Elegbe, J. A. (2016) · Routledge eBooks · doi:10.4324/9781315611822-7 · Cited by 2
Cited by
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., Karachi, C., Leclercq, D., Lafon, C., Chapelon, J.-Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6086 · Cited by 757
“However, because of induced glial and immune reactions observed in animal studies (24), a ~5-cm(3) BBB disruption treatment volume with our device was considered an important achievement, especially if it acts as an “opened gate” for potential locoregional efficacy (14).”
BackgroundOvercoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Spangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695
“Downloaded from https://academic.oup.com/brain/article-abstract/139/4/1265/2464332 by guest on 27 July 2018”
BackgroundMethod
Metadata
- Authors
- Leinenga, G., & Götz, J.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Götz, Jürgen
- Venue
- Science Translational Medicine
- Published
- 2015-03-11
- Volume
- 7
- Issue
- 278
- Pages
- 278ra33-278ra33
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2169076271
- Cited by
- 498
- References
- 40
- Citations by year
- 2026: 24 · 2025: 39 · 2024: 40 · 2023: 50 · 2022: 41 · 2021: 52 · 2020: 51 · 2019: 40 · 2018: 44 · 2017: 55 · 2016: 36 · 2015: 25
- FWCI
- 39.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Australian Research Council (DP130101932)
- National Health and Medical Research Council of Australia (APP1037746, APP1003150)
- ARC Linkage Infrastructure, Equipment, and Facilities (LE130100078)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, non-pharmacological treatment, amyloid plaque clearance, microglia, memory recovery, mouse model
- MeSH terms
- Albumins, Alzheimer Disease, Animals, Blood-Brain Barrier, Cell Count, Disease Models, Animal, Humans, Inflammation, Lysosomes, Memory, Mice, Inbred C57BL, Mice, Transgenic, Phagocytosis, Ultrasonography, Ultrasonics, Amyloid beta-Peptides, Microglia, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.